Evidence map›Paper›PMID 42897198›Full record

ArticleNature microbiology2026

SIV reservoir depletion and clearance from neonatal macaques following transient CCR5 depletion.

Jesse D Deere, David Merriam, Kawthar Machmach, W L William Chang, Michael Nekorchuk, Gema Méndez-Lagares, Hung Kieu, Joseph Dutra, Justin Fontaine, Denise R Andal and 17 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Jesse D DeereDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0002-2539-0338
David MerriamDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0003-1350-3056
Kawthar MachmachDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.
W L William ChangDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0002-1258-7369
Michael NekorchukVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, USA.
Gema Méndez-LagaresDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.
Hung KieuDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.
Joseph DutraDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.
Justin FontaineDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.
Denise R AndalDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0002-4110-7117
Kateland SipeVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, USA.
Elizabeth HeningerVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, USA.
Margaret MartinVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, USA.
Wenze LuDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.
Ning ChinDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.
Connie ChenDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.
Bryant Chi-Thien TranDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA.
Jessica SalinasDepartment of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Corey N MillerDiabetes Center, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-1291-0074
Steven G DeeksDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6371-747X
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Kathleen EngelmanNonhuman Primate Reagent Resource, UMass Chan Medical School, Worcester, MA, USA.
Diogo MagnaniNonhuman Primate Reagent Resource, UMass Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0002-1773-2406
Keith ReimannNonhuman Primate Reagent Resource, UMass Chan Medical School, Worcester, MA, USA.
Mario StevensonDepartment of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Jacob D EstesVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, USA.ORCID http://orcid.org/0000-0002-9652-6394
Dennis J Hartigan-O'ConnorDepartment of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA, USA. dhartigan@ucdavis.edu.ORCID http://orcid.org/0000-0003-4822-636X

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Nonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1M
Resource CoreP40OD028116 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2020 to 2026
$5.9M
Improved RhCMV/SIV vaccine efficacy via IL-10 pathway modulationR01AI143554 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HARTIGAN-O'CONNOR, DENNIS J. · 2018 to 2022
$4.5M
BD FACSymphony S6S10OD036449 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HARTIGAN-O'CONNOR, DENNIS J. · 2024 to 2024
$634k
Effective lethal agents for CCR5???expressing cellsR21AI116230 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HARTIGAN-O'CONNOR, DENNIS J. · 2014 to 2015
$452k
California HIV/AIDS Research Program (CHRP) ID13-D-564U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 75N91019D00024/HHSN261201500003IU.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P40 OD028116U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01 AI143554U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R21 AI116230U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U24 AI126683U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD) P51 OD011107U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD) S10 OD036449
6 · The paper itself

Abstract

Antiretroviral therapy (ART) suppresses viraemia in people with human immunodeficiency virus (HIV), but HIV provirus persists indefinitely in CD4-expressing cells. Cells containing active provirus express viral proteins and have been successfully targeted using broadly neutralizing antibodies (bnAbs). In contrast, cells containing latent provirus cannot be specifically targeted without latency reactivation. Meaningful depletion of the latent HIV or simian immunodeficiency virus (SIV) reservoirs has not been demonstrated except with cytotoxic conditioning for bone-marrow transplantation. Here we show that both the active and latent SIV reservoirs can be eliminated from infant macaques via profound but transient depletion of cells that express CCR5 using a single shot of CCR5/CD3 bispecific antibody. Neonatal rhesus macaques were infected with SIVmac251, then treated with ART beginning at 1 week after infection, followed by treatment with either a CCR5/CD3-bispecific or a CD4-specific antibody, both of which depleted target cells and accelerated the decline in plasma viraemia. Upon ART cessation, while rebound occurred quickly in all animals treated with ART alone, most animals treated with CCR5/CD3 bispecific antibody remained aviraemic for >3 months. Several remained aviraemic to the end of follow-up and efforts to detect replication-competent virus were unsuccessful. Our results show that bispecific antibody treatment achieves meaningful depletion of the replication-competent SIV reservoir and supports the possibility that clinically meaningful depletion of the HIV reservoir might be achievable for recently infected individuals.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.